{"id":6974,"date":"2016-09-22T09:14:25","date_gmt":"2016-09-22T15:14:25","guid":{"rendered":"http:\/\/canadianglycomics.ca\/?p=6974"},"modified":"2019-07-31T15:53:08","modified_gmt":"2019-07-31T21:53:08","slug":"glyco-oncology-discussion-concluded-with-success","status":"publish","type":"post","link":"https:\/\/canadianglycomics.ca\/fr\/glyco-oncology-discussion-concluded-with-success\/","title":{"rendered":"Glyco-oncology discussion concluded with success"},"content":{"rendered":"

\"panel-discussion-1466398-1279x863\"<\/p>\n

By Chardelle Prevatt<\/em><\/p>\n

On Monday, September 19, 2016, GlycoNet scientists joined an elite group of industry experts in\u00a0Montr\u00e9al\u00a0to discuss glycomics and oncology (glyco-oncology).\u00a0<\/strong><\/p>\n

Featuring\u00a0Dr. Greg Plowman, VP\u00a0(oncology research) at Eli Lilly and Company; Dr. Fred Sweeney,\u00a0VP (business development and\u00a0strategic alliances) at bioMerieux; and\u00a0Dr.\u00a0Luc Marengere, Managing Partner of TVM Capital Life Science, the panel offered invaluable advice to GlycoNet scientists and staff alike. Topics included an overview of glyco-oncology, details on GlycoNet research and challenges and opportunities for\u00a0translating Network projects into tangible, commercial advances.<\/p>\n

\u201cWe are truly appreciative of the time given by our industry leaders,\u201d commented\u00a0GlycoNet Scientific Director Dr. Todd Lowary. \u201cWe recognize that our researchers seek to connect and debate relevant topics with their peers and industry colleagues. As such, it is important to facilitate those meetings.\u201d<\/p>\n

Dr.\u00a0Elizabeth Nanak, GlycoNet Executive Director, explained, \u201cThe panel discussion not only triggered the exchange of viewpoints, but allowed our scientists to gain firsthand exposure to world-class industry leaders in the field.\u201d She added, \u201cReal-time interaction and feedback of this nature helps to achieve and maintain success.\u201d<\/p>\n

Canadian Glycomics Network (GlycoNet)<\/strong>\u00a0is a pan-Canadian, multidisciplinary research network aiming to deliver solutions to important health issues and improve the quality of life of Canadians through the study of glycomics. GlycoNet is funded by the\u00a0Networks of Centres of Excellence, a Government of Canada program that supports large-scale, academic-led research networks to build research capacity and accelerate the creation of new knowledge in a specific research area.<\/p>\n

For more information:
\nChardelle Prevatt
\n<\/strong>Associ\u00e9e aux Communications
\nCanadian Glycomics Network (GlycoNet)
\n780.492.4355\u00a0\/\u00a0prevatt@ualberta.ca<\/a><\/p>","protected":false},"excerpt":{"rendered":"

By Chardelle Prevatt On Monday, September 19, 2016, GlycoNet scientists joined an elite group of industry experts in\u00a0Montr\u00e9al\u00a0to discuss glycomics and oncology (glyco-oncology).\u00a0 Featuring\u00a0Dr. Greg Plowman, VP\u00a0(oncology research) at Eli Lilly and Company; Dr. Fred Sweeney,\u00a0VP (business development and\u00a0strategic alliances) at bioMerieux; and\u00a0Dr.\u00a0Luc Marengere, Managing Partner of TVM Capital Life Science, the panel offered invaluable […]<\/p>\n","protected":false},"author":2,"featured_media":11654,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[204],"tags":[15,16,17,18],"class_list":["post-6974","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community","tag-glycomics","tag-industry-leaders","tag-oncology","tag-panel-discussion","wpbf-post"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t